• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » BioSeek awarded new 5-year contract from EPA ToxCast program

BioSeek awarded new 5-year contract from EPA ToxCast program

October 5, 2012
CenterWatch Staff

BioSeek, a drug discovery services company based in San Francisco, has been awarded a significant new contract extending and expanding the company's collaboration with the Environmental Protection Agency (EPA) under the EPA ToxCast screening program. 

The new agreement covers the use of BioSeek's BioMAP Systems human primary cell assay platform to help predict the biological activity and potential toxicity of up to 60,000 additional samples, including environmental chemicals, pesticides, failed pharmaceuticals and nanomaterials.

Under the new agreement, BioSeek will receive up to $46,770,000 over the next five years. The specific value of the award will depend on the volume of testing required during the contract period. The company's previous contract with the EPA awarded in 2007 was for up to $12.8 million over five years.

"Our partnership with EPA under the ToxCast program has been a highly productive relationship with well over 1,000 samples, including chemicals, failed pharmaceutical compounds and nanomaterials analyzed to date. These chemicals included 135 failed pharmaceutical compounds donated by six of the EPA's pharmaceutical company partners. Thus, we view this new and greatly expanded contract as a strong validation of our BioMAP Systems technology," said Ellen Berg, general manager, BioSeek.

Berg continued, "Our efforts are providing EPA with important information relevant to the potential human health effects associated with exposure to a wide range of environmental and other compounds. Additionally this work will expand the BioMAP reference database with a wealth of new information for mining with our pharmaceutical partners to help understand their compounds' safety and activity in the context of human biology, prior to entering costly clinical trials.”

The results from the ToxCast program are aiding the EPA in prioritizing chemicals with the greatest potential health threat for additional, more detailed testing in a cost-effective, efficient manner.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • InputinLights-360x240.png

    Seeking Patient Input Early Helps Ensure Minority Participation in Trials

  • Oncology-360x240.png

    Global Oncology Trial Launches Drop Dramatically During Pandemic, Study Shows

  • Qualification-360x240.png

    Sites and Sponsors Streamlining Qualification Efforts with Technology, Process Revisions

  • New Algorithm Tested and Validated by CSDD Highly Predictive of Patient Burden

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing